MolMed, a biotechnology company focused on research, development, production and clinical validation of gene and cell therapies for the treatment of cancer and rare diseases, announces to have obtained the authorization from AIFA to start phase I-II first in man clinical trials with its own CAR-T CD44v6 for the treatment of patients with acute myeloid leukemia (AML) and multiple myeloma (MM).
The authorization from AIFA follows the positive technical opinion expressed by the Italian National Institute of Health – ISS (Istituto Superiore di Sanità) on March 12th, 2019. The clinical multicenter phase I-II investigation is part of the European project EURE CART Horizon 2020, coordinated and sponsored by MolMed.
The trials foresee the participation of 5 clinical centers: two in Italy (San Raffaele Hospital in Milan, clinical trials coordination center, and Bambino Gesù Children's Hospital in Rome) and three clinical centers in other European countries, Spain, Germany and Czech Republic.
For more information: https://www.molmed.com/